vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and BRAND HOUSE COLLECTIVE, INC. (TBHC). Click either name above to swap in a different company.

BRAND HOUSE COLLECTIVE, INC. is the larger business by last-quarter revenue ($103.5M vs $75.5M, roughly 1.4× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -9.6%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-26.8M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -21.0%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Soho House is an international private members’ club with a focus on the media, arts and fashion industries.

PBYI vs TBHC — Head-to-Head

Bigger by revenue
TBHC
TBHC
1.4× larger
TBHC
$103.5M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+37.3% gap
PBYI
27.7%
-9.6%
TBHC
More free cash flow
PBYI
PBYI
$41.2M more FCF
PBYI
$14.4M
$-26.8M
TBHC
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-21.0%
TBHC

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PBYI
PBYI
TBHC
TBHC
Revenue
$75.5M
$103.5M
Net Profit
$-3.7M
Gross Margin
69.3%
20.4%
Operating Margin
22.7%
-1.9%
Net Margin
-3.6%
Revenue YoY
27.7%
-9.6%
Net Profit YoY
51.8%
EPS (diluted)
$0.26
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
TBHC
TBHC
Q4 25
$75.5M
$103.5M
Q3 25
$54.5M
$75.8M
Q2 25
$52.4M
$81.5M
Q1 25
$46.0M
$148.9M
Q4 24
$59.1M
$114.4M
Q3 24
$80.5M
$86.3M
Q2 24
$47.1M
$91.8M
Q1 24
$43.8M
$165.9M
Net Profit
PBYI
PBYI
TBHC
TBHC
Q4 25
$-3.7M
Q3 25
$8.8M
$-20.2M
Q2 25
$5.9M
$-11.8M
Q1 25
$3.0M
$7.9M
Q4 24
$-7.7M
Q3 24
$20.3M
$-14.5M
Q2 24
$-4.5M
$-8.8M
Q1 24
$-4.8M
$10.1M
Gross Margin
PBYI
PBYI
TBHC
TBHC
Q4 25
69.3%
20.4%
Q3 25
77.7%
16.3%
Q2 25
76.5%
24.9%
Q1 25
77.1%
30.3%
Q4 24
76.4%
28.1%
Q3 24
63.9%
20.5%
Q2 24
77.4%
29.5%
Q1 24
75.5%
32.0%
Operating Margin
PBYI
PBYI
TBHC
TBHC
Q4 25
22.7%
-1.9%
Q3 25
17.6%
-24.7%
Q2 25
12.7%
-12.9%
Q1 25
8.7%
6.2%
Q4 24
22.6%
-2.1%
Q3 24
27.4%
-15.4%
Q2 24
-4.6%
-8.2%
Q1 24
-5.3%
6.4%
Net Margin
PBYI
PBYI
TBHC
TBHC
Q4 25
-3.6%
Q3 25
16.2%
-26.6%
Q2 25
11.2%
-14.5%
Q1 25
6.5%
5.3%
Q4 24
-6.7%
Q3 24
25.2%
-16.8%
Q2 24
-9.6%
-9.6%
Q1 24
-11.0%
6.1%
EPS (diluted)
PBYI
PBYI
TBHC
TBHC
Q4 25
$0.26
$-0.16
Q3 25
$0.17
$-0.90
Q2 25
$0.12
$-0.54
Q1 25
$0.06
$0.61
Q4 24
$0.40
$-0.59
Q3 24
$0.41
$-1.11
Q2 24
$-0.09
$-0.68
Q1 24
$-0.10
$0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
TBHC
TBHC
Cash + ST InvestmentsLiquidity on hand
$97.5M
$6.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$130.3M
$-44.0M
Total Assets
$216.3M
$229.2M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
TBHC
TBHC
Q4 25
$97.5M
$6.5M
Q3 25
$94.4M
$3.6M
Q2 25
$96.0M
$3.5M
Q1 25
$93.2M
$3.8M
Q4 24
$101.0M
$6.8M
Q3 24
$96.7M
$4.5M
Q2 24
$96.8M
$3.8M
Q1 24
$107.2M
$3.8M
Total Debt
PBYI
PBYI
TBHC
TBHC
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
$64.0M
Q4 24
$68.0M
$85.8M
Q3 24
$79.3M
$61.4M
Q2 24
$90.7M
$47.5M
Q1 24
$102.0M
$34.0M
Stockholders' Equity
PBYI
PBYI
TBHC
TBHC
Q4 25
$130.3M
$-44.0M
Q3 25
$115.3M
$-35.2M
Q2 25
$104.7M
$-16.2M
Q1 25
$97.1M
$-19.0M
Q4 24
$92.1M
$-27.1M
Q3 24
$71.1M
$-19.7M
Q2 24
$48.5M
$-5.5M
Q1 24
$51.0M
$3.1M
Total Assets
PBYI
PBYI
TBHC
TBHC
Q4 25
$216.3M
$229.2M
Q3 25
$202.9M
$221.9M
Q2 25
$194.9M
$225.4M
Q1 25
$196.2M
$242.2M
Q4 24
$213.3M
$279.8M
Q3 24
$220.7M
$266.2M
Q2 24
$205.0M
$242.6M
Q1 24
$214.1M
$250.6M
Debt / Equity
PBYI
PBYI
TBHC
TBHC
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×
10.88×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
TBHC
TBHC
Operating Cash FlowLast quarter
$14.4M
$-25.9M
Free Cash FlowOCF − Capex
$14.4M
$-26.8M
FCF MarginFCF / Revenue
19.1%
-25.9%
Capex IntensityCapex / Revenue
0.0%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$-18.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
TBHC
TBHC
Q4 25
$14.4M
$-25.9M
Q3 25
$9.7M
$-7.0M
Q2 25
$14.1M
$-3.1M
Q1 25
$3.6M
$19.8M
Q4 24
$15.6M
$-12.6M
Q3 24
$11.0M
$-12.7M
Q2 24
$1.0M
$-13.7M
Q1 24
$11.2M
$28.2M
Free Cash Flow
PBYI
PBYI
TBHC
TBHC
Q4 25
$14.4M
$-26.8M
Q3 25
$9.7M
$-7.4M
Q2 25
$14.1M
$-3.6M
Q1 25
$3.6M
$19.0M
Q4 24
$15.6M
$-13.1M
Q3 24
$11.0M
$-13.2M
Q2 24
$1.0M
$-14.4M
Q1 24
$26.7M
FCF Margin
PBYI
PBYI
TBHC
TBHC
Q4 25
19.1%
-25.9%
Q3 25
17.7%
-9.8%
Q2 25
26.8%
-4.5%
Q1 25
7.7%
12.8%
Q4 24
26.4%
-11.5%
Q3 24
13.7%
-15.2%
Q2 24
2.1%
-15.7%
Q1 24
16.1%
Capex Intensity
PBYI
PBYI
TBHC
TBHC
Q4 25
0.0%
0.9%
Q3 25
0.0%
0.6%
Q2 25
0.0%
0.7%
Q1 25
0.1%
0.5%
Q4 24
0.0%
0.4%
Q3 24
0.0%
0.5%
Q2 24
0.0%
0.8%
Q1 24
0.0%
0.9%
Cash Conversion
PBYI
PBYI
TBHC
TBHC
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
2.51×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24
2.79×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons